Showing results (121-130 of 161) with videos related to
Sort By:
Pageof 17
BMC Neurology|November 8, 2011
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)Joseph Jankovic, Charles H Adler, P David Charles, et al.Cephalalgia : an International Journal of Headache|September 10, 2024
Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female ratsAgustin Melo-Carrillo, Andrew M Strassman, Khrystoffer-Kihan J Malcolm, et al.Journal of the American Academy of Dermatology|September 12, 2009
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participantsMitchell F Brin, Terry I Boodhoo, Janice M Pogoda, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 17, 2009
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potentialJianghui Meng, Saak V Ovsepian, Jiafu Wang, et al.Basic & Clinical Pharmacology & Toxicology|April 1, 2004
Involvement of a glutamergic mechanism in gamma-dendrotoxin-induced hippocampal neuronal cell loss in the ratGiacinto Bagetta, Ernesto Palma, Silvia Piccirilli, et al.Bioorganic Chemistry|May 20, 2020
Development of a selective inhibitor for Kv1.1 channels prevalent in demyelinated nervesAhmed Al-Sabi, Declan Daly, Myles Rooney, et al.The Journal of Biological Chemistry|December 9, 2010
A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeuticJiafu Wang, Tomas H Zurawski, Jianghui Meng, et al.Headache|May 22, 2010
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programDavid W Dodick, Catherine C Turkel, Ronald E DeGryse, et al.Cephalalgia : an International Journal of Headache|October 15, 2025
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trialPatricia Pozo-Rosich, Andrew M Blumenfeld, Richard B Lipton, et al.Brain : a Journal of Neurology|December 21, 2021
OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patientsLisa Gfrerer, Wenjie Xu, William Austen, et al.Pageof 17